Delivery of siRNA to Ewing Sarcoma Tumor Xenografted on Mice, Using Hydrogenated Detonation Nanodiamonds: Treatment Efficacy and Tissue Distribution

Claveau, Sandra; Nehlig, Émilie; Garcia‐Argote, Sébastien; Feuillastre, Sophie; Pieters, Grégory; Girard, Hugues A.; Arnault, Jean-Charles; Treussart, François; Bertrand, Jean-Rémi

doi:10.20944/preprints202002.0115.v1

Cited by 6 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Key strategies under investigation in the labo ratory and also now in the clinic include attempts to block the function of these oncoproteins, selectively reduce expres sion of the fusion oncogenes, or selectively degrade the fusion oncoprotein. As these nonkinase fusion oncoproteins are true drivers of their associated cancers, these strategies have shown promise in the laboratory (84)(85)(86)(87), though proof of concept is yet lacking in the clinic. Likewise, as these oncopro teins should not exist outside of cancer cells, the therapeutic index of selective approaches to targeting nonfusion kinases is expected to be wide.…”

Section: Targeting Non-kinase Fusion Oncoproteinsmentioning

confidence: 99%

Opportunities and Challenges in Drug Development for Pediatric Cancers

et al. 2021

View full text Add to dashboard Cite

The use of targeted small-molecule therapeutics and immunotherapeutics has been limited to date in pediatric oncology. Recently, the number of pediatric approvals has risen, and regulatory initiatives in the United States and Europe have aimed to increase the study of novel anticancer therapies in children. Challenges of drug development in children include the rarity of individual cancer diagnoses and the high prevalence of difficult-to-drug targets, including transcription factors and epigenetic regulators. Ongoing pediatric adaptation of biomarker-driven trial designs and further exploration of agents targeting non-kinase drivers constitute high-priority objectives for future pediatric oncology drug development. Significance: Increasing attention to drug development for children with cancer by regulators and pharmaceutical companies holds the promise of accelerating the availability of new therapies for children with cancer, potentially improving survival and decreasing the acute and chronic toxicities of therapy. However, unique approaches are necessary to study novel therapies in children that take into account low patient numbers, the pediatric cancer genomic landscape and tumor microenvironment, and the need for pediatric formulations. It is also critical to evaluate the potential for unique toxicities in growing hosts without affecting the pace of discovery for children with these life-threatening diseases.

show abstract

Section: Targeting Non-kinase Fusion Oncoproteinsmentioning

confidence: 99%

Opportunities and Challenges in Drug Development for Pediatric Cancers

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This prevents the formation of secondary tumors ( Lai et al, 2020 ). Nanodiamonds have been used as vector for delivery of siRNA on sarcoma cells ( Claveau et al, 2020 ). Detonation Nanodiamonds (DNDs) have been reported to be useful in radiotherapy.…”

Section: Nanotechnology For Cancer Diagnosismentioning

confidence: 99%

Carbon Based Nanodots in Early Diagnosis of Cancer

et al. 2021

View full text Add to dashboard Cite

Detection of cancer at an early stage is one of the principal factors associated with successful treatment outcome. However, current diagnostic methods are not capable of making sensitive and robust cancer diagnosis. Nanotechnology based products exhibit unique physical, optical and electrical properties that can be useful in diagnosis. These nanotech-enabled diagnostic representatives have proved to be generally more capable and consistent; as they selectively accumulated in the tumor site due to their miniscule size. This article rotates around the conventional imaging techniques, the use of carbon based nanodots viz Carbon Quantum Dots (CQDs), Graphene Quantum Dots (GQDs), Nanodiamonds, Fullerene, and Carbon Nanotubes that have been synthesized in recent years, along with the discovery of a wide range of biomarkers to identify cancer at early stage. Early detection of cancer using nanoconstructs is anticipated to be a distinct reality in the coming years.

show abstract

Cytotoxicity Enhancement of α-Mangostin with Folate-Conjugated Chitosan Nanoparticles in MCF-7 Breast Cancer Cells

Herdiana,

Wathoni,

Shamsuddin

et al. 2023

Molecules

View full text Add to dashboard Cite

α-mangostin (AM) is a promising natural anticancer agent that can be used in cancer research. However, its effectiveness can be limited by poor solubility and bioavailability. To address this issue, chitosan-based nanoparticles (CSNPs) have been investigated as a potential delivery system to enhance the cytotoxicity to cancer cells and improve selectivity against normal cells. In this study, we developed folate-conjugated chitosan nanoparticles (F-CS-NPs) using a carbodiimide-based conjugation method to attach folate to chitosan (CS), which have different molecular weights. The NPs were crosslinked using tripolyphosphate (TPP) via ionic gelation. To characterize the F-CS-NPs, we utilized various analytical techniques, including transmission electron microscopy (TEM) to evaluate the particle size and morphology, Fourier-transform infrared spectroscopy (FTIR) to confirm the presence of functional groups, and ultraviolet-visible spectroscopy (UV-Vis) to measure the absorption spectrum and confirm the presence of folate. The particle size of AM-F-CS-NPs ranged from 180 nm to 250 nm, with many having favorable charges ranging from +40.33 ± 3.4 to 10.69 ± 1.3 mV. All NPs exhibited the same spherical morphology. The use of F-CS-NPs increased drug release, followed by a sustained release pattern. We evaluated the cytotoxicity of AM, AM-F-CS-HMW, and AM-F-CS-LMW NPs against MCF-7 cells and found IC50 values of 8.47 ± 0.49, 5.3 ± 0.01, and 4.70 ± 0.11 µg/mL, respectively. These results confirm the improved cytotoxicity of AM in MCF-7 cells when delivered via F-CS-NPs. Overall, our in vitro study demonstrated that the properties of F-CS-NPs greatly influence the cytotoxicity of AM in MCF-7 breast cancer cells (significantly different (p < 0.05)). The use of F-CS-NPs as a drug-delivery system for AM may have the potential to develop novel therapies for breast cancer.

show abstract

Delivery of siRNA to Ewing Sarcoma Tumor Xenografted on Mice, Using Hydrogenated Detonation Nanodiamonds: Treatment Efficacy and Tissue Distribution

Cited by 6 publications

References 19 publications

Opportunities and Challenges in Drug Development for Pediatric Cancers

Opportunities and Challenges in Drug Development for Pediatric Cancers

Carbon Based Nanodots in Early Diagnosis of Cancer

Cytotoxicity Enhancement of α-Mangostin with Folate-Conjugated Chitosan Nanoparticles in MCF-7 Breast Cancer Cells

Contact Info

Product

Resources

About